SAN JOSE, Calif., Dec. 23, 2019 /PRNewswire/ -- Anixa
Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused
on harnessing the body's immune system in the fight against cancer,
today announced that its chief executive officer, Dr. Amit Kumar, will present at the Biotech Showcase
2020 conference being held January 13-15,
2020 at the Hilton San Francisco Union Square in
San Francisco, California.
During the presentation, Dr. Kumar will highlight recent
corporate and commercial achievements, including the U.S. launch of
Anixa's Cchek™ Prostate Cancer Confirmation (Cchek™ PCC) test, as
well as anticipated milestones for its CAR-T based ovarian cancer
therapeutic and breast cancer vaccine programs.
Details of the presentation are as follows:
Event:
|
Biotech Showcase
2020
|
Date:
|
Monday, January 13,
2020
|
Time:
|
11:00 a.m.
(PST)
|
Track:
|
Franciscan
A
|
Location:
|
Hilton San Francisco
Union Square
|
Anixa will also host one-on-one meetings with investors and
industry stakeholders during the event. Please contact Miriam Miller at Tiberend Strategic Advisors for
availability or to follow-up after the conference.
Biotech Showcase is one of the industry's largest annual
healthcare investor and partnering conferences, bringing together
biopharmaceutical and life sciences company executives, investors,
sector analysts, bankers and industry stakeholders. More than 400
presentations from mid-, small- and micro-cap public and private
companies are expected to present at the event. Qualified
investors and buy- and sell-side analysts are invited to request a
complimentary registration to attend Biotech Showcase and
its sister event, Digital Medicine & Medtech Showcase. For
more information click here.
About Anixa Biosciences, Inc.
Anixa is a
publicly-traded biotechnology company focused on harnessing the
body's immune system in the fight against cancer. Anixa's
therapeutic portfolio includes a cancer vaccine technology focused
on the immunization against α-Lactalbumin to prevent triple
negative breast cancer (TNBC), as well as a cancer immunotherapy
program which uses a novel type of CAR-T, known as chimeric
endocrine receptor T-cell (CER-T) technology. The company's
diagnostic portfolio consists of Cchek™, a liquid biopsy technology
for early detection of solid tumors based on the body's immune
response to the presence of a malignancy. Anixa continually
examines emerging technologies in complementary fields for further
development and commercialization. Additional information is
available at www.anixa.com.
Forward-Looking Statements: Statements that
are not historical fact may be considered forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995. Forward-looking statements are not
statements of historical facts, but rather reflect Anixa's current
expectations concerning future events and results. We generally use
the words "believes," "expects," "intends," "plans," "anticipates,"
"likely," "will" and similar expressions to identify
forward-looking statements. Such forward-looking statements,
including those concerning our expectations, involve risks,
uncertainties and other factors, some of which are beyond our
control, which may cause our actual results, performance or
achievements, or industry results, to be materially different from
any future results, performance, or achievements expressed or
implied by such forward-looking statements. These risks,
uncertainties and factors include, but are not limited to, those
factors set forth in "Item 1A - Risk Factors" and other sections of
our most recent Annual Report on Form 10-K as well as in our
Quarterly Reports on Form 10-Q and Current Reports on Form
8-K. We undertake no obligation to publicly update or revise
any forward-looking statements, whether as a result of new
information, future events or otherwise, except as required by law.
You are cautioned not to unduly rely on such forward-looking
statements when evaluating the information presented in this press
release.
Anixa contact:
Mike Catelani
mcatelani@anixa.com
408-708-9808
Tiberend Strategic Advisors, Inc.
Miriam Miller (Investors)
mmiller@tiberend.com
212-375-2694
Johanna Bennett (Media)
jbennett@tiberend.com
212-375-2686
View original content to download
multimedia:http://www.prnewswire.com/news-releases/anixa-biosciences-to-present-at-biotech-showcase-2020-300978603.html
SOURCE Anixa Biosciences, Inc.